Payment overview · 2025
General Payments
$1,809.84
39 reported records · 15 companies
Healthcare provider profile · identity verified
Samuel Burstein
Allopathic & Osteopathic Physicians|Internal Medicine · CALABASAS, CA · NPI 1124037155
Verified facts
What the public records show
CMS Open Payments records show Samuel Burstein received $1,809.84 in general payments during 2025 across 39 reported records.
Amgen Inc. accounted for 25.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $453.63 | 25.1% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $190.43 | 10.5% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $146.33 | 8.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $144.70 | 8.0% | 2 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $143.76 | 7.9% | 2 | 2025 |
| Mayne Pharma Commercial LLC | Unresolved — no canonical attribution shown | $121.83 | 6.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $118.80 | 6.6% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $115.29 | 6.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $97.37 | 5.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $93.44 | 5.2% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $92.28 | 5.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.79 | 1.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.22 | 1.6% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $18.46 | 1.0% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $14.51 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,809.84 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $292.96 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $146.33 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $143.25 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $122.07 | 1 | 2025 |
Source payment records
|
|||||
| ANNOVERA Normalized: annovera |
Drug | Mayne Pharma Commercial LLC | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| NEXTSTELLIS Normalized: nextstellis |
Drug | Mayne Pharma Commercial LLC | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| BIJUVA Normalized: bijuva |
Drug | MAYNE PHARMA COMMERCIAL LLC | $121.82 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $118.80 | 4 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $118.80 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $116.42 | 1 | 2025 |
Source payment records
|
|||||
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $115.29 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $93.44 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $93.44 | 4 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $92.28 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $89.80 | 3 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $88.38 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $68.36 | 5 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $61.72 | 2 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $58.50 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $49.60 | 2 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $49.60 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.77 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.77 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.67 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.79 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $29.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.28 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.22 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $28.22 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $27.73 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
130 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 476 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 70 |
| Metformin Hcl | Metformin Hcl | 198 | 53 |
| Losartan Potassium | Losartan Potassium | 191 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 166 | 40 |
| Omeprazole | Omeprazole | 154 | 47 |
| Gabapentin | Gabapentin | 153 | 44 |
| Jardiance | Empagliflozin | 130 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 32 |
| Lisinopril | Lisinopril | 120 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | 32 |
| Trazodone Hcl | Trazodone Hcl | 93 | 26 |
| Clonazepam | Clonazepam | 74 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 22 |
| Famotidine | Famotidine | 66 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 18 |
| Metformin Hcl Er | Metformin Hcl | 66 | 17 |
| Alendronate Sodium | Alendronate Sodium | 65 | 18 |
| Rybelsus | Semaglutide | 64 | 16 |
| Celecoxib | Celecoxib | 63 | 17 |
| Eliquis | Apixaban | 63 | 12 |
| Meloxicam | Meloxicam | 62 | 27 |
| Ozempic | Semaglutide | 60 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 13 |
| Carvedilol | Carvedilol | 57 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 14 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 52 | suppressed |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Furosemide | Furosemide | 47 | suppressed |
| Alprazolam | Alprazolam | 46 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 13 |
| Atenolol | Atenolol | 44 | suppressed |
| Glimepiride | Glimepiride | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Allopurinol | Allopurinol | 41 | suppressed |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Vascepa | Icosapent Ethyl | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Finasteride | Finasteride | 38 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | suppressed |
| Procto-Med Hc | Hydrocortisone | 38 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 20 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | 14 |
| Simvastatin | Simvastatin | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 24 |
| Lactulose | Lactulose | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,809.84 · 39 records | Amgen Inc. | AIRSUPRA, ANNOVERA, AREXVY, BIJUVA, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, Doc Band, ENFLONSIA, ETERNA, EVENITY, GARDASIL 9, ImmunoCAP, Intracept, M-M-R II, MOUNJARO, NEXTSTELLIS, NURTEC ODT, OTEZLA, PENBRAYA, PREVNAR 20, QULIPTA, REPATHA, ROTATEQ, SHINGRIX, TRUMENBA, The Cologuard Plus Collection Kit, UBRELVY, VAXELIS, VAXNEUVANCE, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error